John Keilty joined Decibel from Third Rock Ventures, where he served as the general manager of platform operations, responsible for the development and implementation of technology roadmaps for companies across the portfolio. Prior to this role, John was the vice president of information technology and informatics at Infinity Pharmaceuticals, where he owned information systems, software development, computational science, biostatistics, clinical data management and clinical informatics. Before joining Infinity in 2002, John was an early member of Millennium Pharmaceuticals, where he held various roles of increasing responsibility, with broad ownership for the creation, management, implementation and transfer of many of the company’s core genomic technologies. Before Millennium, John worked in the Howard Hughes lab of Michael Green at the University of Massachusetts Medical School, focusing on basic research in transcription and gene splicing. John received his B.A. in biology from Clark University and his M.S. in bioinformatics from Brandeis University.

Heather Wolff joined Decibel in February 2018 as the head of clinical development operations for Decibel Therapeutics. Heather is responsible for Decibel’s clinical operations, regulatory operations, medical writing and data management functions, providing leadership around the company’s development programs. She has a long track record in clinical development, with a focus on building and leading data management groups. Widely recognized as a leader in the space, she has been a key member of both large and small companies including Infinity Pharmaceuticals, Millennium Pharmaceuticals (Takeda), Accenture (ACE), Synta Pharmaceuticals and Genetics Institute (Wyeth). She played a role in successfully gaining FDA approval for Wyeth’s rhBMP-2 in the U.S. and E.U., and also facilitated the acquisition of sNDAs for Millennium’s Velcade product. Heather graduated from Skidmore College with a B.A. in English.

Moxham has over 20 years of drug discovery experience, primarily at Eli Lilly and Company where he most recently served as vice president, quantitative biology. In this role, he helped grow Lilly’s oncology pipeline, developed critical biopharma and academic partnerships and established a state-of-the-art lab facility focused on preclinical and translational research. Previously, he was associate vice president, oncology research at Lilly where he established and led the company’s biomarker group. Moxham began his tenure at Lilly as a research scientist and received several awards from the company, including the Lilly Research Laboratories President’s Award and the Eli Lilly and Co. Global Quality Advocate Award. He also spent two years as a senior research fellow at Merck, where he supported a portfolio of projects centered on Alzheimer’s disease and led work that resulted in a clinical candidate. Moxham serves on the external review boards of the Long Island Bioscience Hub and the Alzheimer’s Drug Discovery Foundation, and on the advisory board of Science Exchange. He has a B.S. in biological sciences from Cornell University and a Ph.D. in molecular and cellular pharmacology from the State University of New York at Stony Brook. He also conducted postdoctoral training at SUNY Stony Brook, sponsored by the National Institutes of Health.

Fraser Stoddart, 2016 Nobel Laureate in Chemistry, was born in Edinburgh, Scotland, in 1942. He obtained all his degrees from Edinburgh University and spent time at Queen’s University, Imperial Chemical Industries and the Universities of Sheffield and Birmingham in the UK before moving to UCLA in the US in 1997. He has mentored 500 undergraduate and graduate students and postdoctoral fellows during his career, has over 1200 publications, and is presently a Board of Trustees Professor of Chemistry at Northwestern University. Stoddart was honored by Her Majesty Queen Elizabeth II as a Knight-Bachelor in her 2007 New Year’s Honors List for his services to chemistry and molecular nanotechnology.

Samuel Stupp is Board of Trustees Professor of Materials Science and Engineering, Chemistry, Medicine, and Biomedical Engineering at Northwestern University. He directs Northwestern’s Simpson Querrey Institute and the Center for Bio-Inspired Energy Science, an Energy Frontiers Research Center funded by the U.S. Department of Energy. Professor Stupp is a member of the National Academy of Sciences, the National Academy of Engineering, the National Academy of Inventors, the American Academy of Arts and Sciences, and the Spanish Royal Academy, and is a fellow of the American Physical Society, the Materials Research Society, and the Royal Society of Chemistry.